|
|
|||||||
Autoimmune Cytopenias |
From Department of Haematology, Barts & The London, Queen Marys School of Medicine and Dentistry, Whitechapel, London, UK (DP, TB, ACN); Department of Medical Sciences, Ospedale "Regina Apostolorum", Albano Laziale (MLE, RS); Dept. of Hematology, "Tor Vergata" University Hospital, Rome, Italy (SA)
Correspondence: Adrian Newland, Department of Haematology, The Royal London Hospital, Whitechapel, London El 2ES, UK. E-mail: a.c.newland{at}qmul.ac.uk
We conducted a retrospective analysis of 11 consecutive patients with various autoimmune cytopenias who failed to respond to conventional treatments and received a fixed-dose regimen of rituximab (100 mg weekly for 4 consecutive weeks). Sustained complete responses were achieved in 4 out of 7 patients with idiopathic thrombocytopenic purpura and in 1 patient with autoimmune pancytopenia. A partial response was observed in 1 patient with autoimmune hemolytic anemia. The immunotherapy had no effect in 1 patient with pure red cell aplasia or in 1 patient with autoimmune neutropenia. No infusion-related or delayed toxicities attributable to rituximab were experienced by any of the patients.
Key words: autoimmune disease, cytopenias, rituximab, low dose.
This article has been cited by other articles:
![]() |
G. Emilia, M. Luppi, M. Morselli, F. Forghieri, L. Potenza, and G. Torelli A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura Haematologica, July 1, 2008; 93(7): 1113 - 1115. [Full Text] [PDF] |
||||
![]() |
F. Zaja, M. L. Battista, M. T. Pirrotta, S. Palmieri, M. Montagna, N. Vianelli, L. Marin, M. Cavallin, M. Bocchia, M. Defina, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura Haematologica, June 1, 2008; 93(6): 930 - 933. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |